AG真人官方

GoDaddy Inc. (GDDY) filed a Form 144 indicating that insider Brian Sharples intends to sell up to 500 common shares through Morgan Stanley Smith Barney on 01 Aug 2025. The proposed sale is valued at $80,235, versus 142,488,191 shares outstanding, making the transaction <0.001% of total float. The filing also discloses two recent sales by Sharples: 500 shares on 02 Jun 2025 for $91,015 and 500 shares on 01 Jul 2025 for $89,840. Shares were originally acquired as restricted stock on 02 Jun 2020. No adverse information is asserted by the filer, and the representation of compliance with Rule 10b5-1 is included. While the dollar amount is modest, investors may monitor the pattern of recurring monthly sales.

Teva Pharmaceutical Industries Ltd. (TEVA) has filed a Form 144 announcing the possible sale of 52,742 ordinary shares through Citigroup Global Markets on or about 01-Aug-2025. The shares carry an estimated aggregate market value of $799,437 and equal roughly 0.005 % of the 1.15 billion shares outstanding, indicating a very small portion of the company鈥檚 float. The seller鈥攁n unnamed insider鈥攔eceived the stock on 01-Aug-2022 via a restricted share-unit (RSU) award. No other sales have been reported in the past three months. A Form 144 is a notice, not a guarantee, but signals that the insider may execute the transaction on the NYSE under Rule 144. Given the modest size and compensation-related origin, market impact is expected to be minimal, though insider sales can be perceived as a slight negative sentiment indicator.

TriSalus Life Sciences, Inc. (TLSI) filed Amendment No. 1 to its Schedule TO (Form SC TO-I/A) dated July 15, 2025. The amendment updates the documentation for the company鈥檚 issuer tender offer and related consent solicitation covering all outstanding shares of its Series A Convertible Preferred Stock.

Key terms reiterated:

• Each preferred share may be exchanged for common stock equal to (Liquidation Preference + accrued dividends through August 10, 2027) 梅 $4.00, subject to customary adjustment mechanisms.
• Concurrent consent solicitation seeks majority approval to amend the Certificate of Designations, enabling the company to mandatorily convert any remaining preferred shares at a conversion ratio 11.3% less favorable than the tender offer rate.

The amendment鈥檚 principal purpose is to replace the Prospectus/Offer to Exchange originally filed on June 23, 2025 with an updated version filed on July 11, 2025 as Exhibit (a)(1)(A) to Form S-4/A (File No. 333-288250). Other disclosures in the original Schedule TO remain unchanged.

Administrative details: The filing confirms the offer is an issuer tender offer under Rule 13e-4, is not a final amendment, and does not invoke cross-border exemptions. CEO Mary Szela signed the certification.

Clover Health Investments (CLOV) 鈥� Form 4 insider filing: CEO and Director Andrew Toy reported an automatic share disposition on 07/01/2025 related to the vesting of previously granted RSUs. A total of 308,950 Class A common shares were withheld to satisfy tax obligations (transaction code 鈥淔鈥�) at a reference price of $2.75. Following the withholding, Toy鈥檚 direct beneficial ownership stands at 10,560,047 shares. The RSU award, originally granted on 01/01/2023 and reported on 01/04/2023, vests quarterly in equal 6.25% installments through 01/01/2027, contingent upon continued service.

The filing reflects a routine, non-open-market administrative transaction rather than an elective sale, and does not indicate a change in Toy鈥檚 long-term ownership intent. No derivative securities or additional open-market trades were reported.

The Form 4 filed on 07/03/2025 reports routine equity-compensation activity by Forte Biosciences (FBRX) CEO, Chair and Director Paul A. Wagner. On 07/01/2025 he converted 1,250 restricted stock units into an equal number of common shares (code M) at a $0 exercise price. To cover statutory taxes, 98 shares were automatically surrendered (code F) at $12.44 each. Following the transactions, Wagner now owns 80,940 FBRX shares directly and retains 7,500 unvested RSUs.

No open-market buying or selling occurred, no cash changed hands, and the share count involved is immaterial relative to Forte鈥檚 public float, so market impact should be limited. Nevertheless, the filing incrementally increases insider ownership and signals that vesting under the 2021 Equity Incentive Plan continues as scheduled.

The Form 4 filed on 07/03/2025 reports routine equity-compensation activity by Forte Biosciences (FBRX) CEO, Chair and Director Paul A. Wagner. On 07/01/2025 he converted 1,250 restricted stock units into an equal number of common shares (code M) at a $0 exercise price. To cover statutory taxes, 98 shares were automatically surrendered (code F) at $12.44 each. Following the transactions, Wagner now owns 80,940 FBRX shares directly and retains 7,500 unvested RSUs.

No open-market buying or selling occurred, no cash changed hands, and the share count involved is immaterial relative to Forte鈥檚 public float, so market impact should be limited. Nevertheless, the filing incrementally increases insider ownership and signals that vesting under the 2021 Equity Incentive Plan continues as scheduled.

Magnachip Semiconductor Corp. (MX) filed a Form 4 disclosing that director Ilbok Lee acquired 55,845 shares of common stock on July 1 2025. The transaction was coded "A" (acquisition) and carries a stated price of $0, indicating a grant, award or other non-cash issuance. Following the transaction, Lee鈥檚 direct ownership increased to 275,026 shares. No derivative securities were involved, and there were no dispositions.

The filing signals a meaningful expansion of an insider鈥檚 equity stake and may be interpreted by investors as a vote of confidence in the company鈥檚 prospects.

Expensify, Inc. (EXFY) 鈥� Form 4 filing dated 07/02/2025

Chief Executive Officer and Chairman David Michael Barrett reported the sale of 30,000 Class A common shares on 07/01/2025 under a Rule 10b5-1 trading plan adopted 03/31/2025. The weighted-average sale price was $2.56, with individual trades executed between $2.47 and $2.63. Aggregate consideration was roughly $77,000.

Following the transaction, Barrett鈥檚 beneficial ownership remains substantial at 1,528,480 shares held indirectly through Barrett Trust LLC plus 210,676 shares held directly. The disposed shares represent 鈮�2.0 % of his indirect holdings, suggesting the sale is modest relative to his overall stake.

The filing is limited to this single planned disposition; no derivative security activity, option exercises, or additional purchases were reported. Because the sale was effected pursuant to a pre-established 10b5-1 plan, it may mitigate concerns over opportunistic timing, yet it still constitutes an insider reduction in exposure.